Schrodinger Inc

SDGR has broken key early-September consolidation support, closing below the rising 9EMA and 20EMA, signaling that buyers can no longer absorb supply and suggesting potential for accelerated downside. Medium-term bias shifts to bearish given the Support Failure pattern, and short-term timing is unfavorable with rejection at EMAs. Execution focuses on sell-side participation into any bounce toward the former support zone near mid-19s, with invalidation on a reclaim and acceptance back above the 9EMA/20EMA area.

• ↑ACV up 27% YoY to $29.6M; FY ACV guide $218–228M
• ↑Q2 total revenue $58.9M; drug discovery rev rose to $23M
• ↓Negative earnings yield and weak profitability factors signal low returns